OCuSOFT announces availability of Ocudox Convenience Kit
RICHMOND, Texas — A prescription-only eyelid disease treatment kit is available at retail pharmacies around the country, the kit’s manufacturer said.
OCuSOFT announced the availability of the Ocudox Convenience Kit for immediate dispensing at such retail pharmacies as Rite Aid, CVS, Walgreens — including Duane Reade — among others.
The kit includes Ocudox capsules (doxycycline hyclate), OCuSOFT Lid ScrubPLUS Extra Strength Pre-Moistened Pads and Tears Again advanced Liposome Spray. The kit includes antibacterial properties designed to eliminate bacteria strains, such as MRSA and Staph epi1.
AmerisourceBergen posts 2.4% increase in revenue
VALLEY FORGE, Pa. — AmerisourceBergen on Thursday posted revenue of $19.8 billion, up 2.4%, for its second quarter ended March 31.
"In the March quarter, we delivered outstanding performance on top of very strong performance last year," stated David Yost, AmerisourceBergen CEO.
"Solid results in all of our business units, combined with better than expected contributions from specialty generics drove results ahead of expectations,” added Steve Collis, AmerisourceBergen president and COO. “Our disciplined working capital management has further strengthened our balance sheet, and we continue to have excellent financial flexibility. Our results continue to demonstrate the strength of our two growth drivers: generics and specialty pharmaceuticals."
Earlier in the quarter, Yost announced his retirement. He will be succeeded by Collis.
AmerisourceBergen also updated its guidance — projecting diluted earnings per share in fiscal year 2011 will be in the range of $2.41 to $2.49.
"The key assumptions supporting the diluted earnings per share range for fiscal year 2011 are: We continue to expect revenue growth of between 2% and 4%, we now expect operating margin expansion in the mid to high single-digit basis points range, and free cash flow is now expected to be in the high end of the range of $625 million to $700 million, which includes capital expenditures now expected to be in the $175 million range,” Yost said. “We have increased our share repurchase expectation for fiscal year 2011 to $598 million from the original expectation of $400 million for the year, subject to market conditions."
Zytiga OKed as prostate cancer treatment
HORSHAM, Pa. — The Food and Drug Administration has approved a new treatment for prostate cancer made by Johnson & Johnson.
Centocor Ortho Biotech, J&J’s biotech subsidiary, announced Thursday the approval of Zytiga (abiraterone acetate), a daily pill for use in combination with the corticosteroid prednisone for treating castration-resistant prostate cancer that has spread to other parts of the body in men who have received prior chemotherapy with Sanofi-Aventis’ Taxotere (docetaxel).
“This FDA approval represents a welcome new option in the treatment of metastatic prostate cancer,” said Howard Scher, Memorial Sloan-Kettering cancer specialist and investigator for the late-stage clinical trial of the drug. “As a clinician, I believe the efficacy and safety profile of abiraterone acetate, as well as its oral, once-daily formulation, will help address the important need for additional therapeutic choices for men living with this serious disease.”